Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome.
To evaluate the efficacy of a terpene mixture (rowatinex) compared to ibuprofen, patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) were randomly selected to either receive rowatinex 200 mg t.i.d. or ibuprofen 600 mg t.i.d. After a 6-week treatment, the decrease in the mean total NIH-CPSI score was significant in both groups from 21.4 to 15.3, (6.1 (p < 0.01) and from 21.2 to 16.8, (4.4 (p = 0.04) in the rowatinex and ibuprofen group, respectively. The rate of definite improvement as defined as 25% improvement in the total score was superior (p = 0.04) in the rowatinex group (68%) versus the ibuprofen group (40%). Judging from these results, rowatinex gave significant symptomatic relief and may be of benefit for many men diagnosed with CP/CPPS. Further, including the placebo-controlled studies are necessary to define its role in the management of this difficult to treat disease.
Lee
Choong Bum
CB
Department of Urology, St. Vincent Hospital, Catholic University College of Medicine, Suwon, Korea.
Ha
U-Syn
US
Lee
Seung Ju
SJ
Kim
Sae Woong
SW
Cho
Yong-Hyun
YH
D000328:Adult; D016009:Chi-Square Distribution; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006305:Health Status Indicators; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage*; D008297:Male; D017699:Pelvic Pain / Q000175:diagnosis / Q000188:drug therapy*; D011336:Probability; D011472:Prostatitis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016037:Single-Blind Method; D013577:Syndrome; D013729:Terpenes / Q000008:administration & dosage*; D016896:Treatment Outcome
D013729:Terpenes; C036965:Rowatinex; D007052:Ibuprofen